ArticleCirculation reports2023

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.

Michihiro Suwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.